Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciforadenant
- Development stage
- Phase 2
- Lead developer
- Corvus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ciforadenant is an investigational small molecule immune checkpoint inhibitor that acts as a selective and reversible antagonist of the adenosine A2A receptor (ADORA2A). By blocking this receptor on immune cells such as T lymphocytes, natural killer cells, macrophages, and dendritic cells, ciforadenant prevents tumor-derived adenosine from suppressing anti-tumor immune responses in the tumor microenvironment. This mechanism aims to restore immune surveillance and promote tumor regression. Ciforadenant is being developed primarily for cancer indications, including renal cell carcinoma and non-small cell lung cancer. The drug was originally discovered by Vernalis and is currently being developed by Corvus Pharmaceuticals in collaboration with Genentech and M. D. Anderson Cancer Center.
- Other names
- ciforadenant
02
Targets
ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on ciforadenant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciforadenant.